Go to Page # Page of 17
loading

Bevacizumab in Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

 R.A. Burger, M.F. Brady, M.A. Bookman, J.L. Walker, H.D. Homesley, J. Fowler, B.J. Monk, B.E. Greer,
  1st-Jul-2010
Description: A Background information on Bevacizumab, Advanced Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer, Gynecologic Oncology Group (GOG) Study which will give you idea on GOG-0218, Ovarian cancer, epithelial ovarian [OV], primary peritoneal [PP], fallopian tube [FT] cancers, Vascular endothelial growth factor (VEGF), Bevacizumab (BEV), monoclonal antibody to VEGF, GOG-0218: Schema, Histologic diagnosis of epithelial OV, PP, or FT cancer.
Views: 2580
Domain: Medical
Category: Biotech/Pharma
weSRCH App on Apple
Contents:
Phase III Trial of Bevacizumab in the Primary p , y Treatment of Advanced Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer: A Gynecologic Oncology Group (GOG) Study
R.A. Burger,1 M.F. Brady,2 M.A. Bookman,3 J.L. Walker,4 H.D. Homesley,5 J. Fowler, B.J. Monk, B.E. Greer, M. Boente S.X. J Fowler 6 B J Monk 7 B E Greer 8 M Boente,9 S X Liang10
Chase Cancer Center, Philadelphia, PA; 2G ... See more

Recent Presentations

...
22 July, 2019
Tine Peeters
21 July, 2019

FDA's Approach to the Opioids Crisis

FDA is working in a prioritized way in multiple areas to confront opioid overdoses while working to ensure patients receive appropriate pain treatment.

...
20 July, 2019